Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes?

If you answer YES to any of the above, now is the time to register for the AIMday in Antimicrobial Resistance.

The event takes place on Thursday 4 July at the Blavatnik School of Government and is hosted by The University of Oxford, together with the NIHR Community Healthcare MIC.

FREE registration for academics is now open and closes on Thursday 27 June (advance registration is essential).

A range of companies are registered to attend, and it will be a fantastic opportunity for researchers looking to network with industry and discuss relevant questions.

Companies registered to attend

  • Abbott
  • Academic Health Science Network for the North East and North Cumbria
  • Amprologix
  • Astrego Diagnostics
  • Centauri Therapeutics
  • Destiny Pharma
  • Evotec
  • GeneFirst
  • GSK
  • Ingenza
  • Innovate UK
  • metaLinear
  • Oppilotech
  • Oxford Drug Design
  • Pedanius Therapeutics
  • Randox Laboratories
  • Release Life Sciences and Diagnostics
  • Summit Therapeutics
  • Thermo Fisher Scientific

To see the questions posed by these companies, please visit aimday.se/amr-2019/questions-listing.

Register here: http://aimday.se/amr-oxford-2019

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.